首页>
外国专利>
Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCRI receptor
Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCRI receptor
展开▼
机译:杂芳基-己酸酰胺衍生物,其制备及其作为MIP-1-α与其CCRI受体结合的选择性抑制剂的用途
展开▼
页面导航
摘要
著录项
相似文献
摘要
Compounds of formula (I) wherein R1 is optionally substituted (C2-C9)heteroaryl; R2 is optionally substituted phenyl-(CH2)m-, naphthyl-(CH2)m-, (C3-C10)cycloalkyl-(CH2)m-, (C1-C6)alkyl or (C2-C9)heteroaryl-(CH2)m-, m is an integer from zero to four; R3 is hydrogen, or optionally substituted (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n-, (C2-C9)heterocycloalkyl-(CH2)n-, (C2-C9)heteroaryl-(CH2)n- or aryl-(CH2)n-, n is an integer from zero to six; or R3 and the carbon to which it is attached form an optionally substituted and/or fused five to seven membered carbocyclic ring; R4 is hydrogen, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, hydroxy (C1-C6)alkyl, (C1-C6)alkoxyCO, (C3-C10)cycloalkyl-(CH2)p-, or optionally substituted (C2-C9)heterocycloalkyl-(CH2)p-, (C2-C9)heteroaryl-(CH2)p-, phenyl-(CH2)p- or naphthyl-(CH2)p-, p is an integer from zero to four; or R4 and R5 together with the nitrogen atom to which they are attached form an optionally substituted (C2-C9)heterocycloalkyl group; R5 is hydrogen, (C1-C6)alkyl or amino. The present compounds are potent and selective inhibitors of MIP-1-alpha. binding to its receptor CCR1, and are thus useful to treat inflammation and other immune disorders.
展开▼
机译:式(I)的化合物,其中R 1是任选取代的(C 2 -C 9)杂芳基; R 2是任选取代的苯基-(CH 2)m-,萘基-(CH 2)m-,(C 3 -C 10)环烷基-(CH 2)m-,(C 1 -C 6)烷基或(C 2 -C 9)杂芳基- (CH 2)m-,m是0至4的整数; R 3为氢或任选取代的(C1-C10)烷基,(C3-C10)环烷基-(CH2)n-,(C2-C9)杂环烷基-(CH2)n-,(C2-C9)杂芳基- (CH 2)n-或芳基-(CH 2)n-,n为0至6的整数; R 3和与之连接的碳形成任选取代和/或稠合的五至七元碳环; R 4是氢,(C 1 -C 6)烷基,羟基,(C 1 -C 6)烷氧基,羟基(C 1 -C 6)烷基,(C 1 -C 6)烷氧基CO,(C 3 -C 10)环烷基-(CH 2)p-或任选取代的(C2-C9)杂环烷基-(CH2)p-,(C2-C9)杂芳基-(CH2)p-,苯基-(CH2)p-或萘基-(CH2)p-,p为整数从零到四; R 4和R 5与它们所连接的氮原子一起形成任选取代的(C 2 -C 9)杂环烷基; R 5为氢,(C 1 -C 6)烷基或氨基。本发明化合物是MIP-1-α的有效和选择性抑制剂。结合其受体CCR1,因此可用于治疗炎症和其他免疫疾病。
展开▼